Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
| Date first appeared online | 02/02/2023 |
| DOI | 10.1016/j.kint.2022.12.028 |
| Authors | Bain S. |
| Journal Name | Kidney International |
| Volume | 103 |
Documents
- 63332.pdf , Book, Copyright ª 2023, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).